Director, Global Translational Lead
Takeda Pharmaceutical Company Limited
Cambridge, Massachusetts, United States
Kondala Atkuri Ph.D. (MBA) is an translational medicine expert with over 20 years of experience in drug development in academic and industry settings combined. His experience spans over several disease focus areas including immune-oncology, autoimmunity and rare diseases, and multiple drug modalities namely small molecules, biologicals, gene and cell therapies.
Kondala obtained his PhD from National Institute of Immunology, New Delhi and a post-doc from Stanford University, CA. Later he transitionaled to a Research scientist role at Schoold of Medicine, Stanford Univerisity where he led studies on the intersection of immune system and energy metabolism in the context of mitochondrial diseases. He then moved to Pfizer, Inc where he held several roles as a preclinical cellular biomarker group lead, Pharmacokinetics, Dynamics and Metabolism (PDM) representative for preclinical development of biologics, and Precision and Translational Medicine lead for early clinical development of small molecules & biologics and gene therapy in autoimmune and rare diseases respectively, He is currently at Takeda where he holds a dual role as a Global Translational Lead for allogeneic and autologous cell therapy programs for heme and solid malignancies and as a Medical Director for Takeda assets in solid tumors.
Disclosure information not submitted.
Tuesday, April 25, 2023
10:30 AM – 11:00 AM ET